Section Arrow
Quote
RNA.NASDAQ
- Atrium Therapeutics Inc.
Quotes are at least 15-min delayed:2026/07/11 06:36 EDT
Regular Hours
Last
 12.46
-0.45 (-3.49%)
Day High 
12.87 
Prev. Close
12.91 
1-M High
13.8 
Volume 
319.92K 
Bid
12.01
Ask
15.75
Day Low
12.2 
Open
12.87 
1-M Low
11.4031 
Market Cap 
220.83M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.26 
20-SMA 12.91 
50-SMA 12.85 
52-W High 16.77 
52-W Low 11.4031 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.02/-2.78
Enterprise Value
220.83M
Balance Sheet
Book Value Per Share
13.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
18.76M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ELABPmgc Holdings Inc1.12+0.06+5.66%-- 
RXRXRecursion Pharmaceuticals3.56-0.2-5.32%-- 
VYNEVYNE Therapeutics0.6376-0.0344-5.12%-- 
HUMAHumacyte0.6937-0.0066-0.94%-- 
GOSSGossamer Bio0.1697-0.0053-3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.